Industry
SEO and GEO for Pharmaceutical and Healthcare Brands in Egypt and the Gulf
Pharmaceutical SEO services for YMYL content held to an evidence standard, usually in two languages, always under regulatory review. Twenty-one of my seventy-two engagements since 2012 have been in this sector — it is the largest share of the roster and the most demanding.
72 named engagements since 2012 · SEO Head at Eye Advertising · SEO & GEO instructor at Learn N’ Digital · Arabic and English
The Roster
Twenty-One Pharmaceutical and Healthcare Engagements
Sanofi Bronchicum · Merck Group KSA · Abbott Group KSA · Jamjoom Pharma KSA · Acino Pharma · ATCO Pharma · Apex Pharma EG · Vitron Pharma · BioPharma EG · BIO Egypt Group · MEDAD Medical KSA · Vaccine Valley · NAOS · Dermazone · Acculab · Dokki Scan · Touches Clinic · Physiowell Dubai · Dr. Dolittle Dubai · DR. Shetiwy · ED Cure
Names are listed as a record of engagements, not as endorsements. This page does not link to client sites, and performance figures for individual accounts are available on request, subject to client permission.
The Problem
Why Pharma Sites Underperform Even When the Content is Good
Pharmaceutical marketing teams rarely have a writing problem. The content is usually accurate, sourced and reviewed — it has been through more scrutiny than almost any other category on the web. It still does not rank, and it almost never gets quoted by an answer engine.
Four reasons, in the order I usually find them:
- The review cycle shapes the structure. Approved copy tends to open with context and qualification and arrive at the answer late, because that is the safe order for a reviewer. It is also the order that makes a passage unquotable.
- The Arabic version was translated, not researched. So it targets phrasings that are correct Arabic and that nobody searches, while the questions patients and prescribers actually type go unanswered.
- Corporate sites are architecturally conservative. Heavy frameworks, gated sections, brand microsites on separate domains, and a rendering setup that means retrieval sees very little of it.
- Nobody owns the entity. The company name, the brand name and the local subsidiary appear differently across the global site, the local site, LinkedIn and directories, so a model cannot resolve who is making the claim.
None of those is fixed by publishing more articles, which is usually what gets proposed.
The Difference
What Changes for Pharmaceutical SEO Services When Content is Regulated
Everything in technical SEO and GEO still applies. What changes is the process around it, and pretending otherwise is how agencies lose pharma accounts in month three.
- Claims cannot be rewritten for clarity. They can be restructured and repositioned on the page, but the wording that was approved stays approved. The craft is in the architecture around the claim, not the claim.
- The reviewer belongs in the room early. A restructuring plan signed off in principle before the work starts saves a quarter of rework. Bringing med-legal in at the end is the single most expensive mistake in this sector.
- Prescription-medicine promotion to the public is restricted across Egypt, Saudi Arabia and the UAE, which shapes what a brand site can target at all. Disease-awareness and health-education content is usually where the searchable demand actually sits.
- E-E-A-T is not a checklist here. Author identity, credentials, citation of primary sources and review dates carry real weight for YMYL queries, and most local pharma sites publish anonymously.
- Two markets, not one Arabic audience. Egyptian and Saudi patients search differently, and the regulatory and product picture differs too.
What I Do
What My Pharmaceutical SEO Services Fix, in This Order
Foundation Audit
Crawl, render and index diagnostics on the corporate site and any brand microsites, including whether AI crawlers can reach them at all. Brand microsites on separate domains are where I find the worst damage.
You get: an indexation and rendering report per property, with the fixes ranked
Bilingual Intent Research
What patients, carers and healthcare professionals actually search, per market, in Arabic and English — researched rather than translated, and separated by Egypt and the Gulf.
You get: a per-market, per-language demand map tied to the pages that should own each question
Restructuring within Approved Copy
Reordering so the approved answer is self-contained and early, with the regulatory context adjacent rather than woven through the sentence. Designed to pass review, not to dodge it.
You get: restructured pages or briefs, annotated so a reviewer can see what did and did not change
Entity and Authorship
Organization and Person schema, named medical reviewers with credentials and review dates, and consistent facts across the global site, the local site and off-site profiles.
You get: a schema spec and an entity consistency checklist across every surface
How It Runs
The Four Stages of a Pharmaceutical SEO Engagement
01 · Week 1–2
Audit and Alignment
Technical baseline, plus a conversation with whoever owns med-legal review about what is and is not changeable.
02 · Week 2–3
Plan, Pre-Approved
The restructuring approach agreed in principle before any page is touched. This is the step that saves the quarter.
03 · Ongoing
Execute
Page by page, through your normal review cycle. I write to the constraint rather than asking for exceptions.
04 · Monthly
Measure
Rankings, and separately whether the approved answer is now being cited by AI engines for the questions that matter.
Markets
Egypt, Saudi Arabia and the UAE are Three Pharmaceutical Markets
Different regulators, different registration pictures, different search behaviour. A single Arabic page serving all three is the most common structural mistake I see, and it underperforms in all three.
Egypt — the largest Arabic-language search volume in the region and the most competitive Arabic health content. Dialectal queries dominate patient-facing search; the Egyptian Drug Authority governs what can be promoted.
Saudi Arabia — higher commercial value per query, thinner Arabic content competition, and a different dialect in patient-facing search. The SFDA governs registration and promotion.
UAE — a far higher share of English-language search than either, a large expatriate audience, and health authorities at both federal and emirate level. Often the market where an English-first strategy is genuinely correct.
I work on the search side of this, not the regulatory side. Your regulatory affairs team owns what may be said; I own whether the approved version can be found and quoted.
Questions
Pharmaceutical SEO Questions Clients Ask
By agreeing the approach before touching a page, and by restructuring rather than rewriting. Approved claim wording stays as approved; what changes is where it sits on the page and what surrounds it. Briefs are annotated so a reviewer can see exactly what changed and what did not, which turns a re-review into a scan rather than a fresh approval.
I work on content that is subject to those regimes, alongside the client’s regulatory affairs team. I am an SEO and GEO consultant, not a regulatory consultant — your RA function decides what may be said, and I make sure the approved version is findable and quotable.
Yes, and for health content it is one of the highest-leverage areas: named authors and medical reviewers with real credentials, primary-source citation, visible review dates, and an organisation entity that resolves consistently. Most local pharma sites publish anonymously, which is a large and fixable disadvantage.
I research the demand per market and either write or brief and review. For regulated claims I prefer to brief, because the text has to go through your review anyway and a brief that respects the constraint moves faster than a draft that ignores it.
Yes. Gated HCP sections need deliberate decisions about what is indexable, what sits behind the gate, and how the public-facing layer supports the gated one without leaking restricted content. Getting this wrong in either direction is common.
Usually more than the team expects. Disease awareness, symptom and condition education, diagnostic pathways, patient support and HCP resources are where the searchable demand sits, and they are also what answer engines are being asked about. The brand benefits from owning the question without promoting the product.
Only with written permission. The names on this page are clients whose work is already public or who agreed to be listed; everyone else is described by category.
Free AI Visibility Audit
Request an Audit of Your Approved Pharmaceutical Content
The audit checks whether crawlers and answer engines can reach and read your site and brand microsites, and whether your Arabic side is visible. No access to your systems required.
Three working days, by email. No call unless you want one, and no follow-up sequence. What the audit covers.
Thank you for your response. ✨
Start Your Pharmaceutical SEO with a Free AI Visibility Audit
Fixed scope, fixed price. You get the findings whether or not we work together afterwards.
Related:
SEO services in Egypt
Industrial & B2B Manufacturing SEO
Fintech, E-Commerce & Technology SEO
Technical SEO & Site Architecture
Arabic & International SEO